73 results about "Cytotoxic Brain Edema" patented technology

The invention relates to the technical field of biological medicines, in particular to a sulfonamide compound for treatment and an enantiomer thereof as well as a preparation method and application thereof, and has the beneficial effects that the provided sulfonamide compound and the enantiomer thereof have the characteristics of strong stability, longer action effect, better drug effect and the like; the compound is a better diuretic and new anti-encephaledema medicine.

The invention belongs to the technical field of disease drugs, and particularly relates to application of an engineered attenuated coxsackie B3 virus vector (CVB3 (mu)) in preparation of drugs for treating traumatic craniocerebral injury. According to the application disclosed by the invention, after severe craniocerebral injury of a mouse, CVB3 (mu) can remodel a host immune system through single intraperitoneal injection treatment, so that the absorption speed of encephaledema on an affected side can be remarkably increased, and the effect of treating traumatic craniocerebral injury is achieved; in addition, the CVB3 (mu) has remarkable safety.

Provided are methods for treatment of pathological conditions causing hemolysis, cerebral edema, acute kidney injury and non-anaphylactic shock, including envenomation, trauma, cerebral malaria and mast-cell diseases using at least one PLA2 inhibitor, alone or in combination with other agents. The unexpected versatility of PLA2 inhibitors, their dosage forms and combinations make them candidates as essential medicines for the developing world.

The invention provides a brain injury simulation human teaching model which comprises a simulation human body with a head, a body and four limbs. A craniocerebral simulation unit for simulating encephaledema, encephaloma, brain fracture, cerebral hernia and cerebrospinal fluid leakage is arranged in the head part; a urinary system simulation unit, a blood circulation system simulation unit and a respiratory system simulation unit are arranged in the body; control programs of response of the urinary system simulation unit, the blood circulation system simulation unit and the respiratory system simulation unit corresponding to different brain injuries are preset in the controller; an operator selects different brain injuries and nurses the brain injuries and complications of the urinary system simulation unit, the blood circulation system simulation unit and the respiratory system simulation unit. The brain injury can be nursed through the craniocerebral simulation unit, the complication of the brain injury can be nursed through the urinary system simulation unit, the blood circulation system simulation unit and the respiratory system simulation unit, and the brain injury nursing system is more consistent with the actual situation and is beneficial to teaching.

The present invention discloses the application of Chinese medicine Polygonum aviculare in the preparation of drugs for preventing and treating stroke. It relates to the field of biomedicine technology. The present invention shows that Chinese medicine Polygonum aviculare can significantly reduce the brain water content and brain index of experimental animals, and can treat brain edema. The drug has the effects of promoting blood circulation and removing blood stasis, can eliminate cerebral vascular blockage and inflammation, resist cerebral vasospasm, maintain normal cerebral vascular function, regulate normal permeability of brain barrier, promote angiogenesis, promote brain nerve function repair and regeneration, and greatly restore the nerve damage and behavioral ability of patients with cerebral stroke. Chinese medicine Polygonum aviculare can be dialectically used for the prevention and treatment of various courses of ischemic stroke and hemorrhagic stroke. The present invention not only provides a new application of Chinese medicine Polygonum aviculare, but also provides a new drug for preventing and treating ischemic stroke and hemorrhagic stroke.

A method of treating or preventing adverse outcomes associated with tissue plasminogen activator (tPA) administration, cerebral edema-related side effects, cerebral edema associated with radiation therapy, or migraine headaches by administering an effective amount of a SUR1-TRPM4 channel inhibitor, such as glyburide, and optionally the co-administration of a second therapeutically active agent, to a subject in need thereof. Adverse outcomes associated with tPA include cerebral hemorrhage, cerebral edema, physical impairment or death. The administration of the SUR1-TRPM4 channel inhibitors occurs prior to the radiation therapy, during the radiation therapy, after the radiation therapy, or combinations thereof. The SUR1-TRPM4 channel inhibitor is administered prior to surgical excision of a brain tumor, CAR-T therapy, or administration of flutarabine. Alternatively, or in addition, the SUR1-TRPM4 channel inhibitor is administered prior the onset of the cerebral edema-related side effects.

This invention discloses a data processing method and system based on the changing trends of image features, relating to the field of cerebral infarction early warning technology. The data processing method includes: feature extraction: processing image data and modal data separately using feature analysis methods to obtain image features, image feature change data, modal data features, modal data feature change data, and the regions where the features are located. In this invention, image data provides intuitive information about brain structure and lesions, while modal data supplements key features such as hemodynamics, brain tissue electrical activity, and electrical impedance from different physiological dimensions. TCD data can monitor blood flow velocity and vascular resistance in real time, BI data is sensitive to changes in pathological states such as cerebral edema, and EEG data reflects subtle changes in neuronal electrical activity. Through feature extraction and analysis, the combination of multi-source heterogeneous data achieves the correction of image feature changing trends, thereby ensuring the accuracy of data processing.

The invention relates to the technical field of medicine, in particular to application of an Acp5 inhibitor in cerebral edema after traumatic brain trauma, and the Acp5 inhibitor comprises a medicine with the ACP5 inhibitor as an active component and a prodrug form of the medicine. According to the invention, through an enzyme-substrate key activation mechanism, a drug is coupled by using an ACP5 specific substrate peptide, dual response release is realized in a lesion area, and the targeting property and the safety are remarkably improved. The prodrug is composed of a core inhibitor module, an ACP5 substrate peptide module and a pH response connection module, and can accurately inhibit ACP5 + macrophage infiltration and reduce encephaledema volume and neuroinflammation. The application can effectively treat acute and chronic encephaledema, reduce off-target effect and side effect, and provide a brand new treatment strategy for traumatic brain trauma.

The present invention discloses a preparation method of rhein / berberine / glycyrrhizic acid hydrogel, which comprises the following steps: dispersing the rhein / berberine nanoparticle solution, glycyrrhizic acid and PBS solution uniformly, and standing to obtain the rhein / berberine / glycyrrhizic acid hydrogel; the concentration of glycyrrhizic acid in the hydrogel is 0.01-0.04 g / mL. The rhein / berberine / glycyrrhizic acid hydrogel prepared by the present invention has the characteristics of anti-inflammation, reducing edema, neuroprotection, etc., solves the limitation of poor curative effect of single-component drugs, realizes in-situ injection administration of three small-molecule drugs, and has synergistic effect, and is applied in drugs for treating inflammatory or edematous encephalopathy accompanied by traumatic brain injury, cerebral edema, Alzheimer's disease, Parkinson's disease, etc., and has obvious therapeutic effect.

The invention relates to the technical field of biological medicine, and particularly discloses a macrophage membrane coated plateau encephaledema drug carrier and a preparation method and application thereof, and the macrophage membrane coated plateau encephaledema drug carrier is composed of a nanoparticle core and a macrophage membrane shell layer wrapping the core; the nanoparticle core comprises an ROS-responsive carrier material and carbon monoxide release molecules MnCO entrapped in the ROS-responsive carrier material; the content of phosphatidylserine in the shell layer of the macrophage membrane is not less than 5 mol% of the total phospholipid of the membrane. According to the invention, a bionic delivery system of ROS response type MnCO nanoparticles coated with a macrophage membrane is constructed, phosphatidylserine on the surface of the membrane is utilized to actively activate a microglial cell Trem2 receptor, a positive feedback cycle of targeting phagocytosis-CO release-Trem2 up-regulation is formed, and at the same time, fatty acid oxidative metabolism reprogramming is promoted by means of degraded membrane lipid, so that the biomimetic delivery system is used for preparing the ROS response type MnCO nanoparticles. And multi-mechanism synergistic efficient brain-targeted therapy is realized.

To provide a compound which can be used for prevention, treatment and control of aquaporin-mediated conditions such as diseases of water imbalance, for example, cerebral edema, a pharmaceutical composition, and a method for producing the same.SOLUTION: There is provided a hydrate of 2 - {[3, 5-bis (trifluoromethyl) phenyl] carbamoyl} - 4-chlorophenyl dihydrogen phosphate represented by the following structure, which exhibits an XRPD pattern comprising at least five 2 θ (°) values selected from the group consisting of 8.8, 9.5, 11.1, 15.2, 15.5, 16.4, 20.2, 20.6, 23.6, 24.0, 24.9 and 27.2, wherein the XRPD is measured using an incident beam of CuK α radiation of 1.54059 Å.SELECTED DRAWING: None

A hypertonic saline (HTS) administration system comprising a sodium sensor for continuous monitoring of sodium concentration of a patient at a predetermined frequency, a infusion pump for delivery of HTS to the patient and a controller for adjusting the infusion rate of an infusion pump based on real-time measurement of sodium concentration of the patient. The sodium sensor comprises a sensor cable for placement through a catheter to position a distal sensor tip at a selected in vivo sensor site. A proximal end of the sensor cable seats within a connector fitting mounted on the catheter at a convenient and accessible subcutaneous position. The connector fitting couples the sensor cable to the controller which adjusts the infusion rate of the infusion pump.

This invention relates to animal models and their applications, specifically to a method for constructing a spontaneous mouse cerebral edema model and its application. This invention utilizes PEN2... fl / + Mice and PEN2 fl / + Mice were mated to obtain PEN2. fl / fl Homozygous mice; then the obtained PEN2 fl / fl Mice and hGFAP Cre / + Mice were mated to obtain PEN2. fl / + hGFAP Cre / + Mice; the final PEN2 obtained fl / + hGFAP Cre / + Mice and PEN2 fl / fl Mice were mated to obtain PEN2. fl / fl hGFAP Cre / + The mouse model is a spontaneous mouse cerebral edema model. In this model, PEN2 protein levels are significantly downregulated, and the mouse exhibits a severe cerebral edema phenotype. This model can be used to establish a cerebral edema drug screening platform. It can also be used for research on cerebral edema-related diseases, such as the pathogenesis of cerebral edema caused by infection, glioma, and traumatic brain injury, as well as for the development of technologies and products for the diagnosis and treatment of related diseases.

The invention belongs to the technical field of biological medicines, and relates to a high-throughput screening method based on cell membrane nano-vesicles and application of a screened drug afloqualone in resisting encephaledema. Through a screening model, it is surprisingly found that the drug afloqualone AFQ on the market has the remarkable effect of inhibiting water inflow and encephaledema. The glibenclamide pharmaceutical composition shows a curative effect superior to that of glibenclamide in an animal model, can effectively reduce the volume of cerebral infarction, reduce the death rate in an acute stage and improve neurological impairment, and is known to have good clinical safety and good clinical application prospects. The invention provides a brand-new treatment strategy with a great clinical application prospect for solving the problem of lack of effective medicines for post-stroke encephaledema at present.

The present invention provides the use of α-asarone in the preparation of a drug for preventing or treating hemorrhagic stroke. The structure of α-asarone is shown in Formula I. It can significantly improve short-term neurological deficits and long-term learning and memory function in model rats, reduce cerebral edema, improve blood-brain barrier permeability, and prevent or alleviate brain tissue atrophy during the recovery period. It has a definite therapeutic effect on animal models of hemorrhagic stroke without significant toxic side effects, and is expected to become a promising drug for the prevention and treatment of hemorrhagic stroke. #imgabs0#

The application relates to application of a furan coumarin compound shown in a formula I to prevention and / or treatment of a nervous system disease related to neuroinflammation. The furan coumarin compound has a protective effect on normoxia + lipopolysaccharide (LPS) and hypoxia + LPS combined induction of mouse stellate glial C8-D1A cell normoxia and hypoxia neuroinflammation models, can promote cell growth, inhibit production of related inflammatory factors, effectively reduce brain water content production, weight loss and key protein expression of a plateau cerebral edema model mouse, and can be developed into a medicine for preventing and / or treating neuroinflammation related diseases.

The invention belongs to the technical field of gene drugs, and particularly relates to application of lncRNA-AU020206 in preparation of drugs for treating cerebral arterial thrombosis, the key effect of the lncRNA-AU020206 in occurrence and development of the cerebral arterial thrombosis is disclosed for the first time, and it is clear that the lncRNA-AU020206 activates ferroptosis signal channels through negative regulation of SLC7A11 expression, so that cerebral ischemia reperfusion injury is aggravated. In-vivo and in-vitro experiments prove that the levels of MDA, ROS and Fe < 2 + > can be remarkably reduced by silencing the lncRNA-AU020206, the expression of GPX4 and SLC7A11 can be up-regulated, the cerebral infarction volume and neurological dysfunction can be reduced, and cerebral edema and apoptosis can be improved. Therefore, the lncRNA-AU020206 not only can be used as a new target for treating the cerebral arterial thrombosis, but also can be used for developing a related diagnostic kit, and has remarkable clinical application prospect and market value.

The invention discloses a method and device for detecting encephaledema based on optomagnetic fusion, and relates to the field of biological detection.The method comprises the steps that to-be-processed optical information and to-be-processed magnetic information of the head of a human body are input into a preset brain tissue parameter detection model to obtain the encephaledema level of the head of the human body; the to-be-processed light information is emergent light information after the head of the human body is irradiated with multi-wavelength near-infrared light; the to-be-processed magnetic information is magnetic induction information corresponding to an excitation magnetic field generated around the head of the human body; the preset brain tissue parameter detection model is obtained by training a sparse automatic encoder deep learning network by adopting a photomagnetic information sample data set; the optomagnetic information sample data set is obtained by determining tissue parameters of each stage of encephaledema according to physiological and physical characteristics of the encephaledema, then performing magnetic field analog simulation and light field analog simulation at the same time, and calculating by adopting a finite element analysis method. The brain edema monitoring system and method can realize real-time and lossless continuous monitoring of brain edema.

The invention belongs to the technical field of biological medicines, and provides application of sodium tyrosol sulfate and a derivative tyrosol compound in preparation of brain health products. The structure of the sodium tyrosol sulfate and the derivative tyrosol compound is shown as a formula I. The sodium tyrosol sulfate and the derivative tyrosol compound can effectively reduce the infarction area after cerebral ischemia and relieve encephaledema caused by cerebral ischemia, and have wide application in the aspects of resisting cerebral ischemia and improving encephaledema and cerebral infarction caused by cerebral ischemia. Meanwhile, learning and memory abilities can be effectively improved, brain function recovery is promoted, and the traditional Chinese medicine composition can be widely applied to treatment of behavior / cognitive dysfunction diseases such as cerebral trauma, cerebrovascular accidents, Alzheimer's disease and Parkinson's disease. And the formula I of the # imgabs0 # is shown in the specification.

The application discloses application of a 2-amino-pyrazine derivative in preparation of a medicine for treating and / or preventing apoplexy and complications, wherein the 2-amino-pyrazine derivative iMAP4K1 is (R)-4-[5-amino-6-[[1-(1-methyl-4-piperidyl)-4-pyrazolyl]oxy]-2-pyrazinyl]-N-[2-(3-fluoro-1-pyrrolidinyl)ethyl]-2,6-dimethylbenzamide; the apoplexy is acute ischemic stroke; and the 2-amino-pyrazine derivative can be used as an active ingredient in a medicine for treating and / or preventing post-stroke brain injury and complications, effectively reducing post-stroke cerebral infarction volume, improving sensory-motor and balance nerve functions, and preventing and treating post-stroke complications such as cerebral edema and acute lung injury.

The present invention discloses the use of a compound in the preparation of a medicament for treating and / or preventing stroke. The compound is 2,3-dihydronaphtho[1,2-b]furan-4,5-dione, and the stroke includes acute ischemic stroke or ischemic reperfusion brain injury. The compound can effectively treat or prevent acute ischemic stroke by alleviating the acute brain injury caused by acute ischemic stroke or ischemic reperfusion, reducing the volume of cerebral infarction after acute ischemic stroke, alleviating cerebral edema after stroke, and improving neurological function after stroke.

The invention belongs to the technical field of nursing vests, and discloses a multi-mode vital sign intelligent nursing vest which comprises a front vest, and a patch opening is formed in the front face of the front vest. By arranging the respiration sensor, the electrocardio sensor, the body temperature sensor and the muscular tension sensor, due to the design of the respiration sensor, the electrocardio sensor, the body temperature sensor and the muscular tension sensor, respiration, electrocardio, body temperature and muscular tension of a patient can be monitored in real time, and monitored data are transmitted to the single chip microcomputer; the single-chip microcomputer monitors vital signs and neurological function changes of a patient in real time through an AI algorithm, automatically warns the risk of encephaledema, epileptic seizure or reperfusion injury, and transmits the monitored vital signs and neurological function changes of the patient to the medical system through the data transmission module. Meanwhile, when it is monitored that the vital signs and the neurological functions of the patient are abnormal, an alarm is given out through the alarm to remind medical staff.

A method for identifying a cerebral edema or a cerebral microhemorrhage in a subject, the method including providing a sample obtained from the subject, comprising a level of one or more biomarkers, wherein the one or more biomarkers comprises one or more GLX-related GAGs, one or more GLX-related PGs, one or more GLX-related GPs, one or more GLX-related GLs, one or more GLX-related GCs, or one or more fragments thereof, or any combination of the aforementioned biomarkers; measuring or detecting the level of the one or more biomarkers in the sample; comparing the level of the one or more biomarkers measured or detected to a reference level for the one or more biomarkers; and identifying the subject as having a cerebral edema or a cerebral microhemorrhage if the level of the one or more of the biomarkers measured or detected from the sample are different than the reference level for the one or more biomarkers.

The invention relates to a heteroaromatic formamide compound and application thereof in medicine. Specifically, the invention relates to a heteroaromatic formamide compound as shown in a general formula (I), a preparation method thereof, a pharmaceutical composition containing the compound and application of the compound as a therapeutic agent, in particular to application of the compound as a therapeutic agent for plasma kallikins, kallikins, kallikins, kallikins, kallikins, kallikins, kallikins, kallikins, kallikins, kallikins and kallikins. The present invention relates to the use of a PKa selective inhibitor and to the use in the treatment and / or prevention of diseases that may benefit from plasma kallikrein inhibition, in particular for the prevention and / or treatment of diabetic macular edema (DME), age-related macular degeneration (AMD), choroidal neovascularization, hereditary angioedema (HAE), cerebral edema after stroke, and the like, and more particularly to the use in the prevention and / or treatment of diabetic macular edema (DME), age-related macular degeneration (AMD), choroidal neovascularization, hereditary angioedema (HAE), cerebral edema after stroke, etc. # imgabs0 #

The application discloses application of a MAC-1 agonist in preparation of a medicine for treating and / or relieving cerebral hemorrhage. Specifically disclosed is the use of Leukadherin-1 (LA-1) or a pharmaceutically acceptable salt, isomer or derivative thereof in preparation of a medicine for treating cerebral hemorrhage and secondary brain injury thereof. The medicine can inhibit the migration of immune cells across the blood-brain barrier, reduce cerebral edema, promote hematoma absorption and reduce neural inflammation by regulating the MAC-1-mediated immune adhesion signal pathway, thereby exerting a neuroprotective effect. Meanwhile, a pharmaceutical composition containing the MAC-1 agonist is provided. The application provides a new target and a drug development strategy for cerebral hemorrhage treatment.

The present application relates to a novel isoquinoline derivative having cell protection activity against edema or nervous system diseases, and in particular to a compound of formula I, or a stereoisomer or a pharmaceutically acceptable salt thereof, and uses of the compound and a pharmaceutical composition comprising same in preparation of drugs for preventing and treating cerebral edema, spinal cord edema, retinal edema, optic nerve edema, cardiac edema and diseases associated with cerebral edema, spinal cord edema, retinal edema, optic nerve edema and cardiac edema, or uses thereof in preparation of drugs for cell protection in nervous system diseases.

A method of treating or preventing adverse outcomes associated with tissue plasminogen activator (tPA) administration, cerebral edema-related side effects, cerebral edema associated with radiation therapy, or migraine headaches by administering an effective amount of a SUR1-TRPM4 channel inhibitor, such as glyburide, and optionally the coadministration of a second therapeutically active agent, to a subject in need thereof. Adverse outcomes associated with tPA include cerebral hemorrhage, cerebral edema, physical impairment or death. The administration of the SUR1-TRPM4 channel inhibitors occurs prior to the radiation therapy, during the radiation therapy, after the radiation therapy, or combinations thereof. The SUR1-TRPM4 channel inhibitor is administered prior to surgical excision of a brain tumor, CAR-T therapy, or administration of flutarabine. Alternatively, or in addition, the SUR1-TRPM4 channel inhibitor is administered prior the onset of the cerebral edema-related side effect.

The invention relates to the technical field of traditional Chinese medicines, and discloses application of donkey-hide gelatin bone-strengthening oral liquid in prevention and treatment of plateau hypoxic polycythemia. The colla corii asini bone-strengthening oral liquid can be used for preparing medicines for reducing the number of red blood cells in the high altitude polycythemia, improving the form and function of the red blood cells in the high altitude polycythemia and improving pulmonary edema and encephaledema caused by the high altitude polycythemia. The colla corii asini bone-strengthening oral liquid is applied to prevention and treatment of the plateau hypoxic polycythemia, and the problems that at present, traditional Chinese medicine formulas for treating the plateau polycythemia clinically are few, and the plateau polycythemia resisting effect is poor can be solved.

This invention discloses a system and apparatus for constructing an animal model of high-altitude cerebral edema (HACE). The resulting animal model successfully simulates the cognitive impairment and neuroinflammatory response associated with HACE, effectively reproducing key pathological features of HACE, such as oxidative stress, neuroinflammation, and neurological impairment. This model can be used to study the pathogenesis, early diagnosis, and potential treatment strategies for HACE. This invention provides a reliable animal model for experimental research and drug screening of HACE-related diseases.